KaydedilenlerDerginizi ekleyin

Dergiler / Medical Science and Discovery / 2017 / Cilt: 4 Sayı: 3

Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors

Tugba GUR
Gulsen ENTERİLİ
Necip PİRİNCCİ
Canan DEMİR
Halit DEMİR
Mehmet KABA
Huseyin EREN
Sayfa
23–26
Yayın Tarihi
2017-03-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our results indicates that Nitric oxide (NO), arylesterase (ARE) and paraoxonase (PON) activities may play an important role in the pathogenesis of renal cell cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Reactive oxygen species (ROS) and antioxidant capacity have been implicated in the pathogenesis of various diseases, and cancers.
📊
Temel Bulgular & Veri:Results: Increased activity of serum nitric oxide (NO) was determined in cancer group.
💡
Sonuç & Katkı:Conclusion: Our results indicates that Nitric oxide (NO), arylesterase (ARE) and paraoxonase (PON) activities may play an important role in the pathogenesis of renal cell cancer.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:ARE · PON · Arylesterase

Abstract

Objective: Reactive oxygen species (ROS) and antioxidant capacity have been implicated in the pathogenesis of various diseases, and cancers. Oxidative stress can cause tumor angiogenesis and may be carcinogenic. However, the relationship between antioxidant capacity and various cancers has been researched in several clinical trials. Materials and Methods: In this study, we aimed to identify serum Nitric Oxide (NO), Arylesterase (ARE) and paraoxonase (PON) activities in patients with renal tumors. Serum ARE, PON and NO levels were measured by spectrophotometer. Results: Increased activity of serum nitric oxide (NO) was determined in cancer group. Serum Arylesterase (ARE) were significantly lower in the patient group than the control group. Increased activity of Serum paraoxonase (PON) were detected in the control group (p < 0.05). Conclusion: Our results indicates that Nitric oxide (NO), arylesterase (ARE) and paraoxonase (PON) activities may play an important role in the pathogenesis of renal cell cancer.

🔖

Bu Makaleye Atıf Yap

GUR, T., ENTERİLİ, G., PİRİNCCİ, N., DEMİR, C., DEMİR, H., KABA, M., EREN, H. (2017). Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Medical Science and Discovery, Cilt: 4 Sayı: 3, 23–26. https://ajindex.com/articles/1003054

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (31)

  1. Curti BD, Renal cell carcinoma. JAMA,. 292, 97–100 (2004)
  2. Chow WH, Devesa SS, and Warren JL et al., JAMA, 281,1628–31(1999)
  3. Dhote R, Pellicer-Coeuret M, Thiounn N, et al., BJU Int.86: 20–7 (2000)
  4. McLaughlin JK, Blot WJ, Devesa SS et al., Renal cancer. In: Schottenfeld D and Fraumeni JF (eds) Cancer Epidemiology and Prevention. New York, NY: Oxford University Press, pp. 1142–55 (1996)
  5. Templar J, Kon SP, Milligan TP, et al., Nephrology Dialysis Transplantation 14, 946–51(1999)
  6. Batcioglu K, Mehmet N, Ozturk IC, et al., Cancer Invest. 24, 18–21(2006)
  7. Nishikawa M, Cancer Lett, 266, 53–9 (2008)
  8. Ray G, Batra S, Shukla NK et al., Breast Cancer Res Treat.59:163–70 (2000)
  9. Wang GQ, Dawsey SM, and Li Y, Cancer Epidemiology, Biomarkers and Prevention, 3,161–66 (1994)
  10. Oberley LW, and Buettner GR, Cancer Research 39: 1141–9 (1979)
  11. Gecit I, Aslan M, Gunes M, et al., J Cancer Res, Clin, Oncol., 138: 739–43 (2012)
  12. Cortas NK, and Wakid NW. Clin. Chem., 36, 1440-1443 (1990)
  13. Erel O. Clin. Biochem, 37, 112–229 (2004)
  14. Erel O, Clin. Biochem, 38, 1103–1111 (2005)
  15. Gülçin I, Oktay M, Küfrevioǧlu, ÖI, and Aslan A, Journal of Ethnopharmacology, 79 (3), 325-329 (2002)
  16. Jaruga P, Zastawny TH, Skokowski J, et al., FEBS Lett. 341(1),59-64 (1994)
  17. Sun Y, and Oberley LW, Free Radical Free Radic, Biol, Med. 21: 335–48 (1996)
  18. Blackburn RV, Spitz DR, Liu X, et al., Free Radic Biol, Med, 26, 419–30 (1999)
  19. Toyokuni S, Okamoto K, Yodoi J, et al., FEBS Lett.16, 3581–3 (1995)
  20. Meyer TE, Liang HQ, Buckley AR, et al., International Journal of Cancer 3: 55–63 (1998)
  21. Mantovani G, MaccioA, Madeddu C, et al., International Journal of Cancer 98: 84–91 (2002)
  22. Szatrowski TP, and Nathan CF, Cancer Res. 51, 794–8 (1991)
  23. Marnett LJ, Mutat Res 424, 83–95 (1999)
  24. Seven A, Civelek S, Inci E, et al., Clinical Biochemistry, 32, 369–73 (1999)
  25. Marnett LJ, Carcinogenesis. 21, 361–370 (2000)
  26. Vo TKO, Druez C, Delzenne N, et al., Carcinogenesis. 9(11), 2009–2013 (1988)
  27. Corrocher R, Casaril M, Bellisola G, et al., Cancer, 58(8), 1658–62 (1986)
  28. Nakada T, Akiya T, Koike H et al., Eur Urol, 14(1), 50–5 (1988)
  29. Ozturk HS, Karaayvaz M, Kacmaz M, et al., Cancer Biochemistry Biophysics, 16, 157–168 (1998)
  30. Ferraris AM, Rolfo M, Mangerini R, et al., Am J Hematol., 47, 237–278 (1994)
  31. Farber CM, Kanganis DN, Liebes LF, et al., Br J Haematol 72, 32–35 (1989).